Corinne Vannier

1.9k total citations · 1 hit paper
15 papers, 1.5k citations indexed

About

Corinne Vannier is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Corinne Vannier has authored 15 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Corinne Vannier's work include Advanced Breast Cancer Therapies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Peptidase Inhibition and Analysis (2 papers). Corinne Vannier is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Peptidase Inhibition and Analysis (2 papers). Corinne Vannier collaborates with scholars based in Germany, United States and Switzerland. Corinne Vannier's co-authors include Thomas Brabletz, Feng Zhu, Douglas S. Darling, Axel zur Hausen, Owen J. Sansom, Tobias Keck, Annika Sonntag, Jennifer P. Morton, Ulrich F. Wellner and Valerie G. Brunton and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Corinne Vannier

11 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

2009 1.4k citations Ulrich F. Wellner, Jörg Schubert et al. Nature Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Corinne Vannier Germany	5	1.1k	768	727	111	106	15	1.5k
Muh Hwa Yang Taiwan	6	900 0.8×	753 1.0×	649 0.9×	106 1.0×	132 1.2×	8	1.4k
Chun-Ju Chang United States	9	980 0.9×	445 0.6×	529 0.7×	79 0.7×	146 1.4×	10	1.3k
Mark J. Hynes United States	7	767 0.7×	502 0.7×	1.2k 1.6×	82 0.7×	96 0.9×	9	1.5k
Chi Tat Lam Hong Kong	10	889 0.8×	549 0.7×	940 1.3×	104 0.9×	87 0.8×	12	1.6k
Dennis Shin-Shian Hsu Taiwan	7	651 0.6×	298 0.4×	538 0.7×	109 1.0×	109 1.0×	8	945
Tieju Liu China	20	764 0.7×	451 0.6×	340 0.5×	129 1.2×	133 1.3×	38	1.0k
Regina Maki Sasahara Brazil	9	701 0.6×	751 1.0×	510 0.7×	56 0.5×	70 0.7×	10	1.3k
Antonina Benfante Italy	10	561 0.5×	314 0.4×	494 0.7×	150 1.4×	75 0.7×	12	1.0k
Dacheng Xie China	20	843 0.8×	492 0.6×	349 0.5×	111 1.0×	93 0.9×	26	1.2k

Countries citing papers authored by Corinne Vannier

Since Specialization

Citations

This map shows the geographic impact of Corinne Vannier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corinne Vannier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corinne Vannier more than expected).

Fields of papers citing papers by Corinne Vannier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corinne Vannier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corinne Vannier. The network helps show where Corinne Vannier may publish in the future.

Co-authorship network of co-authors of Corinne Vannier

This figure shows the co-authorship network connecting the top 25 collaborators of Corinne Vannier. A scholar is included among the top collaborators of Corinne Vannier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corinne Vannier. Corinne Vannier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Welslau, Manfred, Karin Potthoff, Matthias Zaiß, et al.. (2024). Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial. Oncology Research and Treatment. 48(1-2). 1–11.

2.

Martens, Uwe M., Fee Bengsch, Ludger Sellmann, et al.. (2023). The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. BMC Cancer. 23(1). 543–543.

3.

Vannier, Corinne, et al.. (2022). 31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry. Annals of Oncology. 33. S15–S15. 1 indexed citations

4.

Lux, Michael P., Eva Diana Runkel, Corinne Vannier, et al.. (2022). PERFORM: A Non-Interventional Study Assessing The Patients' Treatment Starting With 1L Palbociclib in HR+/HER2- ABC. Future Oncology. 18(36). 3971–3982. 2 indexed citations

5.

Zaiß, Matthias, Jens Uhlig, Thomas Decker, et al.. (2021). Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO. Oncology Research and Treatment. 44(11). 613–621. 6 indexed citations

6.

Dechow, Tobias, Ali Aldaoud, Wolfgang Knauf, et al.. (2021). Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. European Journal Of Haematology. 108(2). 133–144. 4 indexed citations

7.

Staehler, Michael, Andrej Panic, Peter J. Goebell, et al.. (2020). First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. International Journal of Cancer. 148(4). 950–960. 4 indexed citations

8.

Zaiß, Matthias, Jens Uhlig, Thomas Decker, et al.. (2019). An observational study to evaluate the potential of Onlife to improve chemotherapy-induced peripheral neuropathy: Final results of the STEFANO trial.. Journal of Clinical Oncology. 37(15_suppl). e23143–e23143.

9.

Lüftner, Diana, Manfred Welslau, Rüediger Liersch, et al.. (2019). Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study. Annals of Oncology. 30. v135–v135.

10.

Knauf, Wolfgang, Jens Uhlig, Corinne Vannier, et al.. (2018). Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. Blood. 132(Supplement 1). 5662–5662. 1 indexed citations

11.

Preca, Bogdan‐Tiberius, Corinne Vannier, David J. Castro, et al.. (2016). ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer. Oncotarget. 7(50). 83278–83293. 17 indexed citations

12.

Vannier, Corinne, et al.. (2013). Zeb1 Regulates E-cadherin and Epcam (Epithelial Cell Adhesion Molecule) Expression to Control Cell Behavior in Early Zebrafish Development. Journal of Biological Chemistry. 288(26). 18643–18659. 62 indexed citations

13.

Wellner, Ulrich F., Jörg Schubert, Ulrike Burk, et al.. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biology. 11(12). 1487–1495. 1380 indexed citations breakdown →

14.

Schurigt, Uta, Lisa Sevenich, Corinne Vannier, et al.. (2008). Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biological Chemistry. 0(ja). 2550494826–21. 1 indexed citations

15.

Schurigt, Uta, Lisa Sevenich, Corinne Vannier, et al.. (2008). Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biological Chemistry. 389(8). 1067–1074. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact